XML 55 R40.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Fair Value (Narrative) (Details) $ in Thousands |  | 12 Months Ended | 48 Months Ended
--- | --- | --- | ---
Oct. 13, 2015 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($) | Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Change in value of contingent consideration |  | $ (4,078) | $ 969 |
Scenario, Forecast [Member] |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent consideration revenue to target ratio |  |  |  | 1.5
Payment of contingent consideration when commercial milestone achieved time allotment period |  |  |  | 65 days
nContact Surgical [Member] |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Change in value of contingent consideration |  | 4,078 | $ 969 |
Fair value of AtriCure common stock issued at closing | $ 3,757 | 5,660 |  |
Patient Enrollment In Converge IDE Trial [Member] |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Change in value of contingent consideration |  | $ 7,500 |  |
Number of days payment due following enrollment |  | 30 days |  |
Completion Of CONVERGE IDE Trial And Receiving A PMA From FDA [Member] |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Potential contingent consideration reduction, percentage |  | 8.33% |  |
Potential contingent consideration reduction if regulatory milestone not met |  | $ 0 |  |
Number of days payment due following receipt of approval |  | 30 days |  |
Maximum [Member] | Completion Of CONVERGE IDE Trial And Receiving A PMA From FDA [Member] |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Change in value of contingent consideration |  | $ 42,500 |  |

X
- Definition Contingent consideration revenue to target ratio. + References No definition available. + Details
Name: | atrc_ContingentConsiderationRevenueToTargetRatio
Namespace Prefix: | atrc_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of days payment due following enrollment. + References No definition available. + Details
Name: | atrc_NumberOfDaysPaymentDueFollowingEnrollment
Namespace Prefix: | atrc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of days payment due following receipt of approval. + References No definition available. + Details
Name: | atrc_NumberOfDaysPaymentDueFollowingReceiptOfApproval
Namespace Prefix: | atrc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment of contingent consideration when commercial milestone achieved time allotment period. + References No definition available. + Details
Name: | atrc_PaymentOfContingentConsiderationWhenCommercialMilestoneAchievedTimeAllotmentPeriod
Namespace Prefix: | atrc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential contingent consideration reduction, percentage. + References No definition available. + Details
Name: | atrc_PotentialContingentConsiderationReductionPercentage
Namespace Prefix: | atrc_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=atrc_NcontactSurgicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=atrc_PatientEnrollmentInConvergeIdeTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=atrc_CompletionOfConvergeIdeTrialAndReceivingPmaFromFdaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |